Insulin human is under clinical development by Diasome Pharmaceuticals and currently in Phase III for Type 2 Diabetes. According to GlobalData, Phase III drugs for Type 2 Diabetes have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Insulin human’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Insulin human overview

Insulin human (oral HDV-Insulin) is under development for the treatment of type I and type II diabetes. The drug candidate is administered through oral route. Oral HDV-Insulin uses a unique, bionanotechnology based cell targeting system to preferentially deliver insulin to specific sites in the body. It acts by targeting insulin receptor. The drug candidate is developed based on HDV insulin technology. HDV is comprised of proprietary liver-targeting molecules that attach to insulin molecules without changing the structure of the insulin itself.

Diasome Pharmaceuticals overview

Diasome Pharmaceuticals (Diasome) is a pharmaceutical company. It focuses on clinical and commercial development of therapies for diabetes and obesity. The company’s pipeline products include multiple injected and oral formulations of liver targeted insulin’s for both type 1 and type 2 diabetic patients. Diasome’s products include oral HDV insulin, injectable HDV insulin and oral HDV candidates among others. The company’s technology platform Hepatocyte directed vesicle (HDV), a cell targeting system which helps to deliver a wide range of necessary hormones and drugs to the liver. It offers products in the fields of insulin replacement, and hepatic (liver) glucose metabolism. Diasome is headquartered in Cleveland, Ohio, the US.

For a complete picture of Insulin human’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.